"10.1371_journal.pone.0114264","plos one","2014-12-10T00:00:00Z","Daniel Y Heng; James Signorovitch; Elyse Swallow; Nanxin Li; Yichen Zhong; Paige Qin; Daisy Y Zhuo; Xufang Wang; Jinhee Park; Sotirios Stergiopoulos; Christian Kollmannsberger","Department of Medical Oncology, Tom Baker Cancer Center, Alberta Health Services Cancer Care, University of Calgary, Calgary, Canada; Analysis Group, Inc., Boston, Massacusetts, United States of America; Novartis Pharmaceuticals Corporation, East Hanover, New Jersey, United States of America; Department of Oncology, British Columbia Cancer Agency, Vancouver, Canada","Analyzed the data: JS ES NL YZ PQ DYZ. Contributed to the writing of the manuscript: DYH JS ES NL YZ PQ DYZ CK. Design of review protocol: DYH JS ES NL XW JP SS CK. Establish search strategies: DYH JS ES NL YZ PQ DYZ XW JP SS CK. Study selection: NL YZ PQ. Quality assessment of included studies: NL YZ PQ DYZ. Advice on structure and content of paper: XW JP SS.","James Signorovitch, Elyse Swallow, Nanxin Li, Yichen Zhong, Paige Qing and Daisy Zhuo are employees of Analysis Group Inc., which has received funding from Novartis for this research. Xufang Wang, Jinhee Park and Sotirios Stergiopoulos are employees of Novartis. Dr. Christian Kollmannsberger has received advisory board and symposia fees from Pfizer, Sanofi-aventis, and Novartis. Professor Daniel Heng has received advisory board fees and/or played a consultancy role with Novartis, Pfizer, BMS, and Bayer. The authors confirm that this does not alter adherence to PLOS ONE policies on sharing data and materials.","2014","12","Daniel Y Heng","DYH",11,TRUE,NA,NA,6,NA,TRUE,FALSE,FALSE,0,NA,FALSE
